Mihael Polymeropoulos, Vanda Pharmaceuticals CEO

Van­da los­es Het­lioz patent court de­ci­sion, vows to ap­peal and ask for stay on Te­va, Apo­tex com­peti­tors

A fed­er­al judge in­val­i­dat­ed four of Van­da Phar­ma­ceu­ti­cals’ patents for sleep med Het­lioz on Tues­day, ef­fec­tive­ly open­ing the door to gener­ic tasimelteon com­pe­ti­tion from Te­va, Apo­tex and oth­ers. Van­da plans to ap­peal and is ask­ing for a stay against the com­pe­ti­tion in the mean­time.

“Van­da in­tends to ap­peal the de­ci­sion to the Unit­ed States Court of Ap­peals for the Fed­er­al Cir­cuit and to re­quest a stay of mar­ket en­try by Te­va and Apo­tex while the ap­peal is pend­ing,” the com­pa­ny said in a state­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.